Drug Profile
FID 119515A
Latest Information Update: 15 Apr 2019
Price :
$50
*
At a glance
- Originator Alcon
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dry eyes
Most Recent Events
- 09 Apr 2019 Novartis completed the spin-off of Alcon
- 16 Jul 2016 No recent reports of development identified for phase-I development in Dry-eyes in USA (Topical, Drops)
- 04 Jun 2013 Alcon Research completes a phase I trial in Dry eyes in USA (NCT01833117)